Catalyst Pharmaceuticals, Inc. (CPRX)

Environment story

Catalyst Pharmaceuticals is a specialty pharmaceutical company with limited direct operational environmental footprint typical of drug manufacturers. No Scope 1, 2, or 3 emissions data disclosed in 10-K. No net-zero targets identified. No major environmental controversies, toxic waste, or water-consumption conflicts documented. The company manufactures specialty pharmaceuticals and licenses products from third parties; manufacturing performed by contract manufacturers whose environmental compliance is delegated to those third parties. Absence of disclosed emissions data and environmental initiatives results in deductions. Score reflects lack of transparency and absence of stated environmental commitments rather than evidence of poor practices.

Social story

Catalyst Pharmaceuticals demonstrates moderate social performance characteristics typical of specialty pharmaceutical firms. The 10-K reports approximately 58 field personnel for FIRDAPSE® and AGAMREE® marketing, 19 patient assistance liaisons, and 19 medical science liaisons, but does not disclose total workforce headcount, demographic diversity metrics (gender, race/ethnicity representation in leadership or workforce), or CEO-to-worker pay ratios. No documented union-suppression activities, strikes, or labor disputes disclosed. Company maintains robust patient assistance programs for FIRDAPSE® and AGAMREE®, including co-pay assistance and charitable foundation donations to reduce out-of-pocket costs, demonstrating commitment to patient access. Supply chain ethics regarding manufacturing partners not explicitly addressed; reliance on contract manufacturers and third-party licensors introduces potential human-rights risks that are not audited or disclosed. Absence of formal diversity metrics and supply-chain labor audits prevents higher scoring.

Governance story

Catalyst Pharmaceuticals exhibits adequate governance structures with no evidence of severe misconduct or regulatory failures. The 10-K indicates the company is a large accelerated filer with well-established compliance infrastructure, including attestation to Section 404(b) effectiveness of internal controls. No disclosed antitrust proceedings, material SEC fines, consumer-safety regulatory actions, or financial-fraud investigations identified in the 10-K. Board independence percentage not disclosed in the filing; cannot be assessed without proxy statement. Share structure not disclosed as dual-class; single class common stock implied. No active lobbying expenditures disclosed targeting environmental deregulation or consumer-protection rollbacks. Patent litigation against three generic competitors (Hetero, Teva, Lupin) for FIRDAPSE® is ongoing but represents normal intellectual property defense, not governance failure. Settlements reached with Teva and Lupin; Hetero case scheduled for trial March 23, 2026. No evidence of shareholder activism, governance litigation, or board independence issues disclosed. Deduction applied for absence of specific board-independence and lobbying-transparency disclosures in 10-K.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Catalyst Pharmaceuticals, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Catalyst Pharmaceuticals, Inc. in the app for interactive charts and portfolio building.

More in Healthcare